Search
MeiraGTx Holdings PLC
MGTXAdd to Watchlist
13.920USD
+1.120+8.75%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.13BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+8.75%
5 Days
+14.95%
1 Month
+45.45%
6 Months
+78.23%
Year to Date
+75.09%
1 Year
+85.35%
Key Figures
12.950Open
13.940High
1.12MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.38%Turnover Ratio
12.800Prev. Close
12.780Low
11.68MTurnover
LossP/E Static
-19.50P/B
0.00%Div Yield TTM
-51.44%ROA
9.73052wk High
0.96Volume Ratio
-147.79MNet Profit
81.45MShares
-1.4836EPS TTM
1.20Beta
-368.19%ROE
4.55052wk Low
9.06%Amplitude
32.42%Gross Margin
1.13BMarket Cap
10.19Reward/Risk
3.31%Risk Rate
TradingKey Stock Score of MeiraGTx Holdings PLC
Currency: USD Updated: 2026-07-02Key Insights
MeiraGTx Holdings PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MeiraGTx Holdings PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
MeiraGTx Holdings PLC Highlights
StrengthsRisks
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 480.66% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 81.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 81.39M.
Undervalued
The company’s latest PE is -9.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 53.71M shares, decreasing 3.14% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 14.83K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.15.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
28.250
Target Price
+120.70%
Upside Space
MeiraGTx Holdings PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
MeiraGTx Holdings PLC Info
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Ticker SymbolMGTX
CompanyMeiraGTx Holdings PLC
CEOForbes (Alexandria)
Websitehttps://meiragtx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of MeiraGTx Holdings PLC (MGTX)?
The current price of MeiraGTx Holdings PLC (MGTX) is 13.92.
What is the symbol of MeiraGTx Holdings PLC?
The ticker symbol of MeiraGTx Holdings PLC is MGTX.
What is the 52-week high of MeiraGTx Holdings PLC?
The 52-week high of MeiraGTx Holdings PLC is 9.73.
What is the 52-week low of MeiraGTx Holdings PLC?
The 52-week low of MeiraGTx Holdings PLC is 4.55.
What is the market capitalization of MeiraGTx Holdings PLC?
The market capitalization of MeiraGTx Holdings PLC is 1.13B.
Is MeiraGTx Holdings PLC (MGTX) currently rated as Buy, Hold, or Sell?
According to analysts, MeiraGTx Holdings PLC (MGTX) has an overall rating of Buy, with a price target of 28.25.
What is the Earnings Per Share (EPS TTM) of MeiraGTx Holdings PLC (MGTX)?
The Earnings Per Share (EPS TTM) of MeiraGTx Holdings PLC (MGTX) is -1.42.